
    
      Three hundred and twenty-four eligible subjects will be randomly assigned 3:1 to receive
      DWP-450 or placebo. Safety and efficacy will be assessed on Days 2, 7, 14, 30, 90, 120 and
      150. The primary efficacy end point assesses the effectiveness of the DWP-450 against placebo
      on Day 30 in a superiority design.
    
  